MOTS-c and SLU-PP-332 Together: What Is Known
MOTS-c and SLU-PP-332 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.
| Field | MOTS-c | SLU-PP-332 |
|---|---|---|
| Class | Mitochondrial-derived peptide | ERR agonist (not a peptide) |
| Also called | mots | slupp, SLU-PP |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | PCAC voted 7–5 for 503A (Jul 2026) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Human studies we summarised | 7 human (4 randomized or controlled) of 15 summarised | 0 human (0 randomized or controlled) of 7 summarised |
| Typical study doses |
| Not reported in study abstractsPubMed search, 11 Oct 2026 |
| Vial sizes sold | 5 mg, 10 mg, 20 mg, 40 mg | 5 mg |
MOTS-c vs SLU-PP-332
Choosing between the two rather than combining them? The comparison lines them up field by field.
Mouse studies of exercise performance
MOTS-c enhanced physical performance in young, middle-aged and old mice.[19]
SLU-PP-332 increased type IIa oxidative fibres and exercise endurance in mice.[20]
A review of pan-ERR agonists, the class that includes SLU-PP-332, says clinical trials are needed to confirm efficacy and safety in humans.[21]
Sport rules
A metabolite-identification study notes WADA prohibits exercise mimetics and metabolic modulators in sport.[22]
MOTS-c is named in WADA's list among AMPK activators.[2]
Other mouse and human-cell results
An 8-week pan-ERR agonist course in ageing mice reversed age-related increases in albuminuria and podocyte loss.[23]
In myoblasts cultured from inactive women, SLU-PP-332 raised SIRT1 and related markers. These are cultured human cells, not treated patients.[24]
MOTS-c ameliorated hyperglycemia and reduced islet-infiltrating immune cells in NOD mice.[25]
Together
The MOTS-c with SLU-PP-332 search returned 0 PubMed records.
Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("SLU-PP-332"[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key mots-c__slu-pp-332); no arithmetic applied.
Common questions
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 4Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 5Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 6Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 7PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 13PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 17PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 20Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 21[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 22Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
- 23Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 24Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 25Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes.Cell reports · 2021PMID 34320351Accessed 2 Oct 2026
Found an error? Report a correction.